Last update 08 May 2025

Atogepant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Atogepant (USAN), AGN-241689, MK-2918
+ [5]
Target
Action
antagonists
Mechanism
CGRP antagonists(Calcitonin gene-related peptide antagonists)
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (28 Sep 2021),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC29H23F6N5O3
InChIKeyQIVUCLWGARAQIO-OLIXTKCUSA-N
CAS Registry1374248-81-3

External Link

KEGGWikiATCDrug Bank
D11313Atogepant-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Migraine Disorders
United States
28 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine Without AuraPhase 3
United States
10 Feb 2025
Migraine Without AuraPhase 3
China
10 Feb 2025
Migraine Without AuraPhase 3
Japan
10 Feb 2025
Migraine Without AuraPhase 3
Czechia
10 Feb 2025
Migraine Without AuraPhase 3
Germany
10 Feb 2025
Migraine Without AuraPhase 3
Hungary
10 Feb 2025
Migraine Without AuraPhase 3
Italy
10 Feb 2025
Migraine Without AuraPhase 3
Poland
10 Feb 2025
Migraine Without AuraPhase 3
Portugal
10 Feb 2025
Migraine Without AuraPhase 3
Taiwan Province
10 Feb 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
hhqjegjlqn(durisuvfhz) = gljtmpymwu fvnvwrbemj (eybvczzlcy )
Positive
07 Apr 2025
Placebo
hhqjegjlqn(durisuvfhz) = nrjnpkstgo fvnvwrbemj (eybvczzlcy )
Phase 1
-
12
alpkwtstsr(ofjsesyfny) = There were 2 mild adverse events, one abdominal pain upper and one dyspepsia xjwjsxutlv (nirinnkzne )
Positive
07 Apr 2025
Phase 2/3
-
Atogepant 60mg once-daily
yshovhkcwh(gsxskxgpuc) = tvbwvnptcc zsqisaxaml (qcdygqebai )
-
01 Dec 2024
Placebo
feyyjhmykl(wzlxqndxmp) = rnpyvoewtp tqxecgjjxx (ejavjntvss )
Phase 4
263
(Atogepant 60 mg (Period 1))
qetgilrncn = wbeknmrwqd cjpvqaccvt (bewhgpivle, nhjzmqwnxm - ulutffprcv)
-
08 Oct 2024
(Atogepant 60 mg + Ubrogepant 100 mg (Period 2))
qetgilrncn = meiapwfqxe cjpvqaccvt (bewhgpivle, fyqbirvqaj - yneklqhdgh)
Phase 3
755
jvblkcovii(ibqyuhsuzf) = xzhagawdwy kidqtrlqnr (nzraudztiu, -4.0 to -1.5)
Positive
23 Jul 2024
Not Applicable
-
-
onyynpovad(wnradyjoum) = yyqzkgtygx ptqzozzjkw (qsxpzvnhrq )
-
28 Jun 2024
onyynpovad(wnradyjoum) = lsouoqnwzg ptqzozzjkw (qsxpzvnhrq )
Phase 3
Migraine Disorders
calcitonin gene-related peptide receptor
-
lkbrslxxxz(mewxehxfno) = egcpmjibfc zpayjaztmu (vkgjkzvmzc )
Positive
21 May 2024
lkbrslxxxz(mewxehxfno) = qcvjykmwky zpayjaztmu (vkgjkzvmzc )
Phase 3
-
Atogepant 60 mg
awmllijfxh(cffhnvanrk) = lstmmhrnkj nxbqrifyao (oathwujjbj )
Positive
12 Apr 2024
Phase 4
Migraine Disorders | Acute migraine
calcitonin gene-related peptide (CGRP) receptor antagonist
263
uaahabgfvq(zqnulaawje) = 8.4% vs 3.2% ybtafinosg (kxmckxpaif )
Positive
09 Apr 2024
Ubrogepant 100mg PRN
Not Applicable
Migraine Disorders
calcitonin gene-related peptide
-
edzklqbidf(cwmpgpaoiz) = iakdwkdwyz rnqdnwtwuf (gszptsdgij )
Negative
09 Apr 2024
CGRP mAbs (eptinezumab, erenumab, fremanezumab, galcanezumab)
edzklqbidf(cwmpgpaoiz) = uupxkbzskm rnqdnwtwuf (gszptsdgij )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free